Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 4Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 24Breast 16Gastrointestinal 15Thoracic 11Head & Neck 3Sarcoma 2Genitourinary 2Tumor-Agnostic 1Other 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Taxes × Dermatologic × Clear all
NCT00110019 2015-10-19

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
823 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡